Literature DB >> 1552338

Calculation of a gallbladder ejection fraction: advantage of continuous sincalide infusion over the three-minute infusion method.

H A Ziessman1, F H Fahey, D J Hixson.   

Abstract

The purpose of this study was to investigate alternative methods of infusing sincalide for calculation of a gallbladder ejection fraction (GBEF) during cholescintigraphy (5 mCi 99mTc-mebrofenin). After gallbladder filling, three methods of infusion were compared in 23 normal volunteers: (1) 0.02 microgram/kg as a 3-min infusion, (2) 0.02 microgram/kg as a 30-min infusion, and (3) 0.01 microgram/kg as a 30-min infusion (14 subjects), all performed on separate days. With the 3-min infusion, the emptying pattern was usually exponential and completed in 15 min. The mean (GBEF) was 52% +/- 26% at 20 min and 56% +/- 27% at 30 min (range 0%-100%). GBEFs were less than 35% in six subjects and 35%-38% in four. Side effects were noted by 11/23 subjects. With the slow infusions, emptying was linear; no side effects were noted. With 0.02 microgram/kg, the mean GBEF was 50% +/- 27% at 20 min and 70% +/- 22% at 30 min (range 26%-95%). Similar results were seen with 0.01 microgram/kg, but the data were more limited. The 30-min infusion had a higher normalcy rate than the 3-min method (91% versus 74%). Females had significantly lower GBEFs than males (p less than 0.05%). We conclude that the slow infusion method is preferable; it is more physiological, results in more complete emptying, has no side effects, has less normal variability, and should improve the specificity of this test. The lower mean female GBEF may have pathophysiological significance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1552338

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

1.  "Characterization of basal hepatic bile...".

Authors:  Harvey A Ziessman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-11       Impact factor: 9.236

2.  Normokinetic biliary dyskinesia: a novel diagnosis.

Authors:  Christopher DuCoin; Robert Faber; Marlon Ilagan; William Ruderman; Daryl Wier
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

Review 3.  Controversies concerning pathophysiology and management of acalculous biliary-type abdominal pain.

Authors:  Amit Rastogi; Adam Slivka; Arthur James Moser; Arnold Wald
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

Review 4.  Cholecystectomy for biliary dyskinesia: how did we get there?

Authors:  Klaus Bielefeldt; Shreyas Saligram; Susan L Zickmund; Anwar Dudekula; Mojtaba Olyaee; Dhiraj Yadav
Journal:  Dig Dis Sci       Date:  2014-09-06       Impact factor: 3.199

Review 5.  Progress and direction of gastrointestinal nuclear medicine.

Authors:  H Ziessman
Journal:  Eur J Nucl Med       Date:  1994-11

Review 6.  Gallbladder dyskinesia: fact or fiction?

Authors:  Geoffrey Francis; John Baillie
Journal:  Curr Gastroenterol Rep       Date:  2011-04

7.  HIDA scan ejection fraction does not predict sphincter of Oddi hypertension or clinical outcome in patients with suspected chronic acalculous cholecystitis.

Authors:  S B Young; M Arregui; K Singh
Journal:  Surg Endosc       Date:  2006-12       Impact factor: 4.584

8.  Gallbladder ejection fraction and symptom outcome in patients with acalculous biliary-like pain.

Authors:  Nuri Ozden; John K DiBaise
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

9.  The role of (99m)technetium-labelled hepato imino diacetic acid (HIDA) scan in the management of biliary pain.

Authors:  K Riyad; C R Chalmers; A Aldouri; S Fraser; K Menon; P J Robinson; G J Toogood
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

10.  Effect of nitric oxide on gallbladder motility in patients with acalculous biliary pain: a cholescintigraphic study.

Authors:  László Madácsy; Borbála Velosy; Attila Szepes; Zoltán Szilvássy; László Pávics; László Csernay; János Lonovics
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.